

## Welcome and Methods

- [Introduction](#)
- [Methods](#)
- [Table 1. Summary of the Process and Methods for the Guidance Development](#)
- [Table 2. Rating System Used to Rate Level of Evidence and Strength of Recommendation](#)
- [Table 3. Commonly Used Abbreviations and Their Expansions](#)

## Evaluate, Test, Monitor

- [Testing, Evaluation, and Monitoring of Hepatitis C](#)
- [HCV Testing and Linkage to Care](#)
- [Testing and Linkage to Care: Table 1 - FDA-approved, Commercially Available Anti-HCV Screening Assays](#)
- [Testing and Linkage to Care: Table 2 - Measures to Prevent Transmission of HCV](#)
- [Testing and Linkage to Care: Table 3 - Common Barriers to HCV Treatment and Potential Strategies](#)
- [Testing and Linkage to Care: Figure 1 - CDC Recommended Testing Sequence for Identifying Current HCV Infection](#)
- [When and in Whom to Initiate HCV Therapy](#)
- [Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens](#)
  
- [Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy](#)
- [HCV Resistance Primer](#)

## Treatment-Naive

- [Initial Treatment of HCV Infection](#)
- [Treatment-Naive Genotype 1](#)
- [Treatment-Naive Genotype 1a Without Cirrhosis](#)
- [Treatment-Naive Genotype 1a With Compensated Cirrhosis](#)
- [Treatment-Naive Genotype 1b Without Cirrhosis](#)
- [Treatment-Naive Genotype 1b With Compensated Cirrhosis](#)
- [Treatment-Naive Genotype 2](#)
- [Treatment-Naive Genotype 2 Without Cirrhosis](#)
- [Treatment-Naive Genotype 2 With Compensated Cirrhosis](#)
- [Treatment-Naive Genotype 3](#)
- [Treatment-Naive Genotype 3 Without Cirrhosis](#)
- [Treatment-Naive Genotype 3 With Compensated Cirrhosis](#)
- [Treatment-Naive Genotype 4](#)
- [Treatment-Naive Genotype 4 Without Cirrhosis](#)
- [Treatment-Naive Genotype 4 With Compensated Cirrhosis](#)
- [Treatment-Naive Genotype 5 or 6](#)

## Treatment-Experienced

- [Retreatment of Persons in Whom Prior Therapy Failed](#)
- [Treatment-Experienced Genotype 1](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis](#)

- [Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 1b Patients Without Cirrhosis](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosis](#)
- [NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients Without Cirrhosis](#)
- [NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients With Compensated Cirrhosis](#)
- [Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis](#)
- [Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosis](#)
- [NS5A Inhibitor DAA-Experienced Genotype 1 Patients](#)
- [Treatment-Experienced Genotype 2](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 2 Patients Without Cirrhosis](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosis](#)
- [Sofosbuvir + Ribavirin-Experienced, Genotype 2 Patients With or Without Compensated Cirrhosis](#)
- [Treatment-Experienced Genotype 3](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosis](#)
- [DAA-Experienced \(Including NS5A Inhibitors\), Genotype 3 Patients With or Without Compensated Cirrhosis](#)
- [Treatment-Experienced Genotype 4](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 4 Patients Without Cirrhosis](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis](#)
- [DAA-Experienced \(Including NS5A Inhibitors\), Genotype 4 Patients, With or Without Compensated Cirrhosis](#)
- [Treatment-Experienced Genotype 5 or 6](#)
- [Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients With or Without Compensated Cirrhosis](#)
- [DAA-Experienced \(Including NS5A Inhibitors\), Genotype 5 or 6 Patients With or Without Compensated Cirrhosis](#)

## Unique Populations

- [Management of Unique Populations with HCV Infection](#)
- [Patients With HIV/HCV Coinfection](#)
- [Patients With Decompensated Cirrhosis](#)
- [Patients Who Develop Recurrent HCV Infection Post Liver Transplantation](#)
- [Patients with Renal Impairment](#)
- [Kidney Transplant Patients](#)
- [Management of Acute HCV Infection](#)
- [HCV in Pregnancy](#)
- [HCV in Children](#)

## References

- [Reference list sorted by first author](#)